Apogee Therapeutics Inc (APGE) Stock Analysis
Verdict: WATCH (do not buy)
AbbVie's $10.9B acquisition at ~$135 locks the price; current levels offer negligible upside with high opportunity cost.
Investment score: 48/100
Analysis as of
Is Apogee Therapeutics Inc stock worth reviewing? AI model thesis
The investment thesis has shifted from clinical biotech to a finalized M&A exit. At $132.88, the stock is trading within 2% of the median analyst target ($135) and the implied acquisition price. 10 major analysts downgraded the stock to 'Neutral' or 'Hold' on June 23, signaling the upside is capped.
7-factor investment score
- Valuation: 10/100 (weight 20%)
- Financial Health: 60/100 (weight 15%)
- Technical Momentum: 50/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Apogee Therapeutics Inc opportunities and risks
What speaks for APGE
- Arbitrage Spread Capture
What speaks against APGE
- Regulatory Blockage (FTC)
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| APGE | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.9% |
| ARWR | n/a | 18.1x | n/a | 100.0% | -48.4% | -0.5% |
| SMMT | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.6% |
| BMRN | 40.4x | 3.4x | 21.0x | 75.9% | 8.3% | 7.0% |
| KRYS | 43.9x | 24.0x | 47.5x | 92.8% | 53.9% | 2.4% |
| CYTK | n/a | 94.1x | n/a | 90.3% | -784.0% | -5.5% |
| Peer median | n/a | 18.1x | n/a | 90.3% | 0.0% | -0.5% |
Frequently asked questions about Apogee Therapeutics Inc (APGE)
Is APGE stock a good investment?
The cached TradeMates AI model rates Apogee Therapeutics Inc as WATCH (do not buy) with an investment score of 48/100. The investment thesis has shifted from clinical biotech to a finalized M&A exit. At $132.88, the stock is trading within 2% of the median analyst target ($135) and the implied acquisition price. 10 major analysts downgraded the stock to 'Neutral' or 'Hold' on June 23, signaling the upside is capped. This is algorithmic model output, not personal investment advice.
Is APGE stock a buy?
The TradeMates model verdict for APGE is WATCH (do not buy) with an investment score of 48/100. Treat this as a model signal to review, not a personal buy recommendation.